Trial Profile
A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals
- 03 Nov 2022 Results(n=31: from two phase 2 studies (E1201 and E1202 NCT02148133, NCT02404025) assessing the effect of eltrombopag on cytomorphologic findings in Patients With Aplastic Anemia published in the American Journal of Clinical Pathology
- 05 Oct 2017 Status changed from active, no longer recruiting to completed.
- 22 May 2017 Planned primary completion date changed from 1 Feb 2017 to 31 Oct 2017.